1Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol- lowering treatment:prospective meta-analysis of data from 90,056 partici- pants in 14 randomised trims of statins [ J ]. Lancet, 2005 ; 366 ( 9493 ) : 1267-78.
2Amarenco P, Bogousslavsky J, Callahan AS, et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in choles- terol levels (SPARCL) study [ J ]. Cerebrovasc Dis, 2003 ; 16 ( 4 ) : 389- 95.
5Guijarro C. High-sensitivity C-reactive protein : potential adjunct for global risk assessment in the primary prevention of cardiovascular disease[J].Circulation, 2001 ; 104 ( 22 ) :E 127.
8Pickup JC, Crook MA. Is diabetes mellitus a disease of the innate immune system [ J ]. Diabetologia, 1998 ;41 (10) : 1241-8.
9Festa A, D'Agostino R Jr,Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the insulin resistance atherosclerosis study[J].Diabetes, 2002;51(4) :1131-7.
10Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angtins[J].J Am Coil Cardiol, 2001 ;37 (5) : 1266-70.
1Yang W,Lu J,Weng J,et al.Prevalenee of diabetes among men and wom- en in China[J].N Engl J Med,2010,362(12): 1090-1101.
2The Accord Study Group.Effects of intensive glucose lowering in type 2 diabetes[J]. N Engl J Med, 2008,358(24) : 2545-2559.
3Accord Study Group.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]. N Engl J Med,2010,362(17) : 1575-1585.
4Scott R,O Brien R,Fulcher G,et al.Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome [J].Diabetes Care, 2009,32(3) : 493-498.
